These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 19810174

  • 1. Comparison of the in-vitro activities of ceftazidime and new cephalosporins against 107 strains of Pseudomonas aeruginosa and 249 strains of cefazolin-resistant Enterobacteriaceae.
    Thabaut A, Durosoir JL, Saliou P.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():123-5. PubMed ID: 19810174
    [Abstract] [Full Text] [Related]

  • 2. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [Abstract] [Full Text] [Related]

  • 3. The in-vitro activity of ceftazidime against clinically important pathogens.
    Knothe H, Dette GA.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():33-41. PubMed ID: 19810167
    [Abstract] [Full Text] [Related]

  • 4. The in-vitro activity of three anti-pseudomonal cephalosporins against isolates from patients with cystic fibrosis.
    Kelly N, Falkiner FR, Keane CT, Murphy M, Fitzgerald MX.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():175-8. PubMed ID: 19802982
    [Abstract] [Full Text] [Related]

  • 5. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN, Barry AL, Thornsberry C, Gerlach EH, Fuchs PC, Gavan TL, Sommers HM.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [Abstract] [Full Text] [Related]

  • 6. Hydrolysis of cefazolin by enzymes produced by Pseudomonas aeruginosa after exposure to ceftazidime in vitro.
    Papaioannidou P, Nitsas V, Mirtsou-Fidani V.
    Vojnosanit Pregl; 2009 Oct; 66(10):785-90. PubMed ID: 19938755
    [Abstract] [Full Text] [Related]

  • 7. Ceftazidime: comparative in-vitro study.
    Verbist L, Verhaegen J.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():67-71. PubMed ID: 19802971
    [Abstract] [Full Text] [Related]

  • 8. An evaluation of the activity of cephalosporins against Pseudomonas aeruginosa.
    Bauernfeind A.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():111-7. PubMed ID: 19810172
    [Abstract] [Full Text] [Related]

  • 9. Comparative in-vitro activity of ceftazidime (GR 20263) and other beta-lactamase stable cephalosporins against pseudomonas. Effect of inoculum size and divalent cation supplementation.
    Chow AW, Bartlett KH.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():345-8. PubMed ID: 19803012
    [Abstract] [Full Text] [Related]

  • 10. Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.
    Adamsson L, Dornbusch K, Hallander HO.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():153-62. PubMed ID: 19802979
    [Abstract] [Full Text] [Related]

  • 11. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL, Smith RP, Ritz W.
    Chemotherapy; 1994 Sep; 40(6):391-8. PubMed ID: 7842822
    [Abstract] [Full Text] [Related]

  • 12. In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamases.
    Livermore DM, Williams RJ, Williams JD.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():163-7. PubMed ID: 19802980
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.
    Hachem R, Reitzel R, Rolston K, Chaftari AM, Raad I.
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115350
    [Abstract] [Full Text] [Related]

  • 14. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I.
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method.
    Hoogkamp-Korstanje JA, Meijer CA.
    Eur J Clin Microbiol; 1982 Jun; 1(3):166-70. PubMed ID: 6293813
    [Abstract] [Full Text] [Related]

  • 16. [Pseudomonas aeruginosa: acquired in vitro resistance to beta-lactams].
    Thabaut A, Meyran M.
    Pathol Biol (Paris); 1983 May; 31(5):387-91. PubMed ID: 6413939
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN.
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of BRL 36650, a new penicillin.
    Van Landuyt HW, Lambert A, Boelaert J, Gordts B.
    Antimicrob Agents Chemother; 1986 Feb; 29(2):362-6. PubMed ID: 3087281
    [Abstract] [Full Text] [Related]

  • 19. Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Pitart C, Marco F, Keating TA, Nichols WW, Vila J.
    Antimicrob Agents Chemother; 2015 Feb; 59(6):3059-65. PubMed ID: 25753646
    [Abstract] [Full Text] [Related]

  • 20. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA, Bassetti M, Duncan LR, Castanheira M.
    J Antimicrob Chemother; 2017 May 01; 72(5):1386-1395. PubMed ID: 28165526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.